In Reply In their Letter to the Editor, Markman and Daneker’s call for advertising guidelines is welcome, but their suggestion to have industry write those guidelines is not. Industry's financial conflicts are too strong, and its track record too weak to pass the laugh test as a credible source of guidance.
Instead, guidelines should be written by an independent third-party entity that explicitly serves the public interest. The Federal Trade Commission (FTC), for example, might be ideal: the commission understands the issues and has vast experience scrutinizing ads. Because claims in the advertisements sometimes involve tests, drugs and devices, a joint FTC-US Food and Drug Administration taskforce might make sense to ensure sufficient content area expertise.
Schwartz LM, Woloshin S. Cancer Care Institutions and Advertising—Reply. JAMA Intern Med. 2016;176(12):1877–1878. doi:10.1001/jamainternmed.2016.6960
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: